'War on Iran not over until its extremist regime falls', says Mossad chief Barnea
250 feared dead in Andaman Sea as overcrowded trawler containing Rohingya refugees capsized
Chaos at TVK chief Vijay's rally: 15 faint due to severe heat and overcrowding in Tiruppur
RCB vs LSG, Match 23 IPL 2026: Head-to-head record, squads, predicted Playing XI and more
Trump dials PM Modi as leaders discuss Iran war, reopening of Strait of Hormuz
INDIA
)
Lung infection and lung injury were the cause of many deaths in the second wave of COVID-19. Doctors everywhere tried their best to find a drug that cured the lung infection. Now, a new preclinical study from researchers at Weill Cornell Medicine and Cold Spring Harbor Laboratory has shown a ray of hope. According to them, an FDA-approved drug that has been in clinical use for more than 70 years may protect against lung injury and the risk of blood clots in severe COVID-19 and other disorders that cause immune-mediated damage to the lungs. The results of their study were published in 'JCI Insight'. The study found that the drug disulfiram protected rodents from immune-mediated lung injury in two separate models of this type of injury: infection with the SARS-CoV-2 coronavirus that causes COVID-19, and a lung failure syndrome called TRALI that in rare cases occurs after blood transfusion.